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Several studies focusing on brain irradiation are in progress. Reﬂecting updates of rele-
vant  outcomes in palliative treatment of patients suffering from brain metastases, the
primary objective of these studies is the evaluation of neurocognitive function and quality
of  life. Improvements of technology in radiation oncology allows us to spare the hip-
pocampal region while appropriately irradiating other parts of brain tissue. Irradiation
of  the hippocampus region is likely to lead to manifestations of adverse events with a
subsequent impact on patient’s quality of life, which is in fact an improper approach in pal-
liative medicine. Ongoing studies evaluate results of hippocampus avoiding radiotherapyrain metastases
ecision-making
ersonalized medicine
compared to standard whole brain radiotherapy. Incorporation of neurocognitive function
assessment may result in the conﬁrmation of superiority of sparing the region of hippocam-
pus  and thus change current style of providing brain irradiation.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
is not to destroy all cancer cells and cure the patient, but.  Background
pproximately 30% of patients develop brain metastases (BM)
s a part of their cancer disease.1 This number is expected
o grow due to an increasing number of registered prepara-
ions from targeted therapy drugs, improvement of surgical
nd radiotherapy methods and an increased availability of bet-
er palliative and supportive care. Increasing incidence of BM
s also due to improvements in imaging technologies and their
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higher availability.2 Brain metastases are considered to be one
of the most serious complications of cancer disease, which
dramatically increase the morbidity and mortality. Their opti-
mal  treatment remains controversial, mainly with respect to
the aim of provided medical care.3 In most cases of patients
with metastases (MTS) of any location, the treatment aimcz (P. Pospísˇil), dolezelova@mou.cz (H. Dolezˇelová),
to reduce actual difﬁculties and prolong the overall survival
with good quality of remaining life by achieving an appro-
priate reduction of symptoms and prevention of its further
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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impairment.4 Besides the reduction of symptoms, the goal
of a good palliation is to minimize its side effects. In order
to achieve this aim, it is important to determine appropriate
end-points not only in relation to an individual patient, but
also in relation to the ongoing randomized clinical trials (RCT)
as resources for future treatment guidelines. Recently, more
attention has been paid to symptom-related outcomes of care,
especially to neurocognitive functions (NCF) and quality of life
as the most frequently mentioned issues.5
One of the standard therapeutic methods of brain metas-
tases is radiotherapy (RT), which offers several possibilities
to inﬂuence further progression of disease. Apart from the
basic technique, i.e. radiation of the whole brain (WBRT –
whole brain radiotherapy), new treatment methods are being
put into practice, such as stereotactic methods of intracra-
nial radiosurgery or radiotherapy. These novel methods allow
delivering higher doses of radiation into a small amount
of tissue. However, these techniques remain available only
for a small group of patients.6 Recently, a lot of trials have
been conducted to compare different radiotherapy techniques
as separate methods of treatment to their combinations.
Other studies deal with a combination of radiotherapy and
neurosurgery.
In most patients the radiation of the whole brain is indi-
cated because of numerous brain metastases present or
because of unmanageable extracranial illness. Thus, attention
must also be paid to the development of further improve-
ments in providing WBRT,  especially in the light of new
knowledge about radiation brain injury mechanisms and
in respect to the personalized palliative approach to each
patient. In this article, we  focus mainly on the whole brain
radiotherapy.
In general, one of the main future directions in the
treatment of cancer patients is the implementation of
so called tailor-made personalized medicine into clinical
practice. That means optimization of drug prescription based
on patient’s individual gene proﬁle in a narrower sense.
Although this concept applies particularly to systemic treat-
ment with chemotherapeutic agents, some principles of
this philosophy could be implemented into other areas of
care for cancer patients, meaning the pursuit of individual-
ized approach to the treatment. One of the basic principles
of tailor-made personalized medicine is the usage of a
speciﬁc procedure for the speciﬁc patient, in order to max-
imize, if possible, the therapeutic effect while avoiding side
effects.
In relation to the facts mentioned above, it is necessary to
take into account some patient-speciﬁc variables while mak-
ing decisions about indications to cranial irradiation. At ﬁrst,
the question is if patient can realistically beneﬁt from being
provided such irradiation. In practice it is about responsi-
ble life expectancy estimation (for example expressed by the
Karnofsky Performance Scale) and about considering all con-
sequences relating to the actual possibilities to provide the
care. If RT is indicated, the next question is what part of brain
should be irradiated and how. Choosing the right procedure
is important in relation to the assessment of all beneﬁts and
risks of our intervention. We summarize some recent recom-
mendations in the use of WBRT  and mention some future
directions related to this issue.iotherapy 1 8 ( 2 0 1 3 ) 133–138
2.  Indications  for  WBRT
In daily radiotherapy practice, one of the most important fac-
tors in decision-making is the level of technical equipment
in a particular radiotherapy department. Not all departments
are able to provide their patients with the most advanced
care, e.g. precise stereotactic radiosurgery (SRS), or WBRT  with
simultaneous integrated boost (SIB) to BM using volumetric
modulated arc therapy delivered by helical tomotherapy or by
linear accelerators (Rapid Arc, IMAT/VMAT therapy).7 Thus,
also because of this technical limitation, WBRT  remains the
most commonly radiotherapy method used in the treatment
of patients with brain metastases.
When considering the best speciﬁc type of treatment it is
important to compare all its pros and cons. In general, pallia-
tive treatment should be as undemanding as possible in order
not to burden patients with long complex treatment. Cost of
this care should be low or at least weighed against potential
beneﬁts in comparison with other lower or more  expensive
alternatives.3
Before starting treatment it is useful to recognize the num-
ber of BM – single lesion, oligometastatic (2–3) or multiple
impairments. It is also very important to properly assess
the general performance status and consider other speciﬁc
clinical situations (presence or absence of extracranial metas-
tases). These are the most common prognostic/predictive
factors mentioned in recent guidelines. Karnofsky Perfor-
mance Scale (KPS) is the most useful tool to estimate patient’s
ability to proﬁt from any kind of treatment. Indeed, KPS is a
part of all tools for stratiﬁcation of patients into prognostic
groups – Recursive Partitioning Analysis and Graded Progno-
stic Index (RPA and GPI score).8,9 Patients with KPS of less
than 70% (RPA group III) will beneﬁt from WBRT  compared to
other type of brain radiotherapy regardless of the type of brain
impairment.
Several studies have been performed to assess the impor-
tance of the implementation WBRT  in combination with local
treatment of brain metastases.10–13 Abe et al.14 reviewed these
ﬁndings and concluded, that initial local brain radiotherapy
without its whole irradiation does not inﬂuence overall sur-
vival, but results in a signiﬁcant increase in brain tumor
recurrence (BTR), while the inclusion of WBRT  into the primary
treatment prolongs time to recurrence and prevents neuro-
logic death.14
Brain tumor recurrence means the clinical progression
resulting in severe impact on patient’s quality of life. BTR
is the most important cause of additional deterioration of
NCF. It seems that it is useful to stratify patients into the
low and high risk group of BTR and hence determine the
indication for WBRT.11 Aoyama also evaluated the risk of
developing brain metastases in breast cancer patients after
up-front WBRT  according to the risk of BTR. Patients in
high BTR risk group (2 or more  BM,  presence of extracra-
nial metastases) who underwent WBRT  developed BTR in
other site of brain in 21% at 6 months compared to 57%
of patients without WBRT.  Patients in the low BTR risk
group (single BM, no extracranial metastases) with and with-
out WBRT  developed BTR at 6 months in 9%, vs. 31%,
respectively.15
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WBRT  as a separate up-front treatment is a possible option
or all prognostic groups in both most common scoring sys-
ems – RPA and GPA. That means that the choice of the type of
adiotherapy offered to patients of the low risk group depends
ostly on the technical equipment of the radiotherapy depart-
ent. Patients with poor prognostic factors (RPA III group)
eneﬁt from WBRT  alone the most.
.  Performing  WBRT
n general, one of the most important outcomes in RCT is
verall survival. Considering that most of patients presented
ith brain metastases die because of the progression of their
xtracranial disease, the overall survival seems not to be the
est factor to assess during decision making for manage-
ent of brain metastases. It is more  important to consider
he aim of our treatment and that is, as obvious in the pallia-
ive approach, symptoms relief, attempt to improve the overall
urvival while maintaining appropriate quality of life, in accor-
ance with the general principle of “primum non nocere”.
his means maintaining good mental conditions, too. More
ecently, endpoints in brain tumor clinical trials have been
eﬁned, with emphasis put on the neurocognitive assessment
nd evaluation of the quality of life.5,16
Results of studies comparing different radiotherapy tech-
iques report some changes in cognitive functions due to
adiation.17 The most serious cause of its alteration is a recur-
ence of cancer disease in brain; its risk might be assessed
y BTR as mentioned above.18 The risk of relapse is, however,
maller if aggressive therapy for brain metastases is used. It is
ssential to ﬁnd a compromise between the beneﬁts of such
ggressive treatment in the sense of reducing the risk of later
ntracranial progression versus higher risk of iatrogenic alter-
tion of cognitive functions and thus decrease in the quality
f life, which is a very important endpoint for a good pal-
iation. The impact of WBRT  on reducing incidence of brain
umors relapse has been demonstrated in several RCTs. The
mission of WBRT  results in a relative increase of a BTR from
0% to 300% (calculated in the original article from absolute
TR risk with and without WBRT,  which was 18% and 70%,
espectively).19
Li et al.20 conﬁrmed that there is a correlation between
umor regression after WBRT  and the improvement of some
ypes of NCF. In contrast, memory-related NCF had a lower
orrelation with rated reduction of MTS  deposits, suggesting
ifferent mechanisms of alteration of different kinds of NCF by
ranial irradiation.20 Nevertheless, it is clear, that WBRT  plays
n important role in protecting patients from decline in some
ypes of NCF.
In fact, the development of brain metastases is based on
ematogenous dissemination from primary or other sites.
mpairment probability of certain parts of the brain depends
lso on its perfusion. 80% of all brain blood supply is deposited
n the telencephalon, so it is the most frequently affected
art.21 But it is true that the whole brain can be seeded by
M,  therefore, WBRT  seems to be the best approach to control
rain metastases.
The standard technique of WBRT  involves the use of
wo opposed contralateral radiation ﬁelds with homogenoustherapy 1 8 ( 2 0 1 3 ) 133–138 135
irradiation of the whole brain.22 Shielding the eyes and other
parts of splanchnocranium is performed using multileaf colli-
mator at most. This technique requires only a simple planning
with minimal personal and technical burden. The whole pro-
cess of radiotherapy can be planned on the 2D X-ray simulator,
so it is available also in the absence of the CT simulator. In this
setting of WBRT,  the whole brain is homogenously irradiated.
The radiation dose is the same in areas of proven MTS  as it
is in areas without apparent MTS. However, it remains uncer-
tain whether it is important to irradiate all parts of the brain,
especially the region of the hippocampus. Provided that the
hippocampus is unimpaired, it seems that beneﬁts of its irra-
diation do not outweigh the potential risk of radiation injury.
Alteration in the processes of learning or spatial memory
processing is related to hippocampal injury.23 The relation-
ship between hippocampal radiation injury and alteration of
NCF has been demonstrated also by Monje et al.24,25 It is esti-
mated, that only 3% of all BM are located in perihippocampal
parts of the brain (within 5 mm of the hippocampus)26. New
methods of WBRT  have been developed in order to minimize
the side effects resulting from irradiation of the hippocampal
region.
4.  Future  directions
With a development of other therapeutic methods and with an
increase in effectiveness of supportive and symptomatic treat-
ment, the prolongation of overall survival in certain groups of
patients is achieved after WBRT.  These are mainly patients
suffering from breast cancer.27 We may expect the manifesta-
tion of long-term side effects of radiation to develop in these
patients, including at most, the impairment of cognitive func-
tions. Some degree of cognitive function alteration can be
observed at baseline, due to the primary status of cancer dis-
ease and other factors.28 In recent years, there has been a
discussion on the signiﬁcance of damage of neuronal stem
cells due to ionizing radiation, with impact on changes of
cognitive functions.29 Neuronal stem cells are located in the
hippocampal subgranular zone of the dentate gyrus. Their sig-
niﬁcance in relation to the process of learning and memory
recall has been demonstrated in many  studies.30,31
Nowadays, randomized clinical trials comparing the ther-
apeutic results using different radiotherapy techniques are in
progress, where the hippocampus region is protected in cer-
tain groups of patients.32 Protecting of the hippocampus is
ensured by using intensity modulated radiotherapy enabling
high conformal radiotherapy with a steep dose gradient in
locations with high priority of sparing. Providing this mod-
ern therapy places high demands on the accuracy of radiation
and precision of planning. Despite RT techniques, the use of
simple planning, as described above, is being developed.33
The avoidance of the hippocampus in WBRT  with evaluation
memory  delayed recall as a primary objective is a subject of
ongoing prospective RTOG study (RTOG 0933).34 Key studies
and reviews reﬂecting preclinical and clinical evidence sup-
porting performance of hippocampus-avoiding whole brain
radiotherapy are summarized in Table 1.
The growing interest in optimizing care of patients with
brain metastases is also reﬂected in the growing number of
136  reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 133–138
Table 1 – Key studies and reviews demonstrating preclinical and clinical evidence supporting performing of
hippocampus-avoiding whole brain radiotherapy.
Author Year Conclusion Consequences
Abe14 2012 Omission of WBRT results in increasing of
BTR
WBRT is still an important part of RT
management of brain metastases.
Importance of selective indications for
local treatment only
Meyers5 2012 Quality of life optimization of brain tumor
patients is essential while prolongation of
overall survival is achieved
Emphasis on the neurocognitive
assessment and evaluation of quality of
life in ongoing trials
Bayer35 and Eriksson30 1982 and 1998 New granule cells are generated from
neuronal stem cells located in the dentate
gyrus
Neuronal stem cells hypothesis approved
Collier36 1987 Memory function are associated with
dentate gyrus of the hippocampus
Hippocampal damage will result in
memory function decline
Mizumatsu25 2003 Pathogenesis of RT-induced NC deﬁcit is
in relation with NSC
CNS  is not exclusively radio-resistant
organ
Abayomi23 and Jalali37 1996 and 2010 There is evidence in radiotherapy of brain
and NC function impairment
Hippocampal sparing RT can reduce
memory impairment after WBRT
Gondi38 2010 There is ability of modern RT techniques
to spare region of hippocampus while
delivering appropriate dose into the other
parts of brain
Superiority of hippocampal - avoidance
WBRT must be evaluated by a prospective
clinical trial
Mehta34, RTOG 0993 study 2012 A Phase II Trial of Hippocampal
Avoidance During Whole Brain
Radiotherapy for Brain Metastases
Prospectively evaluation of the NC beneﬁt
of hippocampal sparing during RT
adiotWBRT, whole brain radiotherapy; BTR, brain tumor recurrence; RT, r
nervous system.
studies and articles dealing with this subject. As showed in
Fig. 1, there is a clear growth in publishing review articles
on WBRT  linked at MEDLINE PubMed. Current year’s results
are interpolated to 12 months to allow comparison with other
years. Discussing of NCF is their part mainly at last 6 years.
Standardized regular assessment of neurocognitive functions
in patients with radiotherapy of brain is an essential step
forward to implementation of modern radiotherapy methods
into clinical practice.
If ongoing studies conﬁrm that patients undergoing
hippocampus-avoiding WBRT  do not have increased risk of
brain tumor recurrence while better preserving the neu-
rocognitive function as a result of radiation to brain injury,
providing hippocampus sparing radiotherapy will become the
new method of choice. Then, it will be necessary to correctly
estimate the risk of development of brain metastases in the
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Fig. 1 – Number of new publications in PubMed database
when entering given keywords as mentioned in graph.herapy; NC, neurocognitive; NSC, neuronal stem cells; CNS, central
perihippocampal region and to incorporate this factor into
upgraded scoring systems.
It might be assumed that the withholding of WBRT  will
not be the subject of further research. As suggested in sev-
eral studies (mentioned above) comparing the local treatment
of brain metastases with WBRT,  WBRT  leads to a signiﬁcant
reduction in the risk of brain tumor recurrence and in the risk
of neurological death. While providing the hippocampal spar-
ing brain irradiation using modern radiotherapy techniques,
it is also possible to increase the dose of radiation to areas of
proven metastases (SIB). Combining these two  approaches in
a particular patient case, may improve the efﬁcacy of radiation
therapy while reducing the risk of late side effects. This means
an individualized care as a type of personalized medicine in a
wider sense.
Taking into account an increasing number of patients with
brain metastases, studies dealing with this subject are becom-
ing an important direction of further radiotherapy research.
There is also an increasing number of diagnoses of early
asymptomatic BM, because of examination of patients in rela-
tion to their enrollment into some clinical trials, where MRI  of
brain is performed as one of inclusion criteria. In these cases, a
decision making is inﬂuenced by the consideration of speciﬁc
trial enrollment criteria and by the fact, that these patients are
often long survivals.
5.  SummarySeveral studies focusing on brain irradiation are in progress.
Reﬂecting updates of relevant outcomes in palliative treat-
ment of patients suffering from brain metastases, the primary
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unction and quality of life. Improvements of technology in
adiation oncology allows us to spare the hippocampal region
hile appropriately irradiating other parts of brain tissue.
rradiation of the hippocampus region is likely to lead to man-
festations of adverse events with a subsequent impact on
atient’s quality of life, which is in fact an improper approach
n palliative medicine. Ongoing studies evaluate results of hip-
ocampus avoiding radiotherapy compared to standard whole
rain radiotherapy. Incorporation of neurocognitive function
ssessment may result in the conﬁrmation of superiority of
paring the region of hippocampus and thus change current
tyle of providing brain irradiation.
onﬂicts  of  interest
one declared.
cknowledgements
he work was supported by the European Regional Devel-
pment Fund and the State Budget of the Czech Republic
RECAMO, CZ.1.05/2.1.00/03.0101).
This study was funded by Institutional Resources for Sup-
orting the Research Organization provided by the Ministry of
ealth of the Czech Republic in 2012.
Supported by European Regional Development Fund –
roject FNUSA-ICRC (No. CZ.1.05/1.1.00/02.0123).
Supported by MZCR IGA NT/14600.
Supported by MZCR IGA NT/14120.
 e  f  e  r  e  n  c  e  s
1. Wen PY, Black PM, Loefﬂer JS. Metastatic brain cancer. In:
DeVita V, Hellman S, Rosenberg SA, editors. Cancer: principles
and  practice of oncology. Philadelphia, PA: Williams &
Wilkins/Lippincott; 2001. p. 2655–70.
2. Seute T, Leffers P, ten Velde GP, Twijnstra A. Detection of
brain metastases from small cell lung cancer: consequences
of  changing imaging techniques (CT versus MRI). Cancer
2008;112(8):1827–34.
3. Marc D, Okunieff P, Milano MT. Brain metastases. In:
Gunderson LL, Tepper JE, editors. Clinical radiation oncology.
Philadelphia: Elsevier Saunders; 2012. p. 421–38.
4. National Comprehensive Cancer Network (NCCN). NCCN
Clinical Practice Guidelines in Oncology. Palliative care Version
2.2012;  2012. Online at http://www.nccn.org/professionals/
physician gls/pdf/palliative.pdf. Version 2 (last accessed
09.09.12).
5. Meyers CS, Rock EP, Fine HA. Reﬁning endpoints in brain
tumor clinical trials. J Neurooncol 2012;108(2):227–30.
6. Linskey ME, Andrews DA, Asher AL, et al. The role of
stereotactic radiosurgery in the management of patients
with newly diagnosed brain metastases: a systemic review
and evidence-based clinical practice guideline. J Neurooncol
2010;96:45–68.
7. Saminathan S, Chandraraj V, Sridhar CH, Manickam R.
Comparison of individual and composite ﬁeld analysis using
array detector for intensity modulated radiotherapy dose
veriﬁcation. Rep Pract Oncol Radiother 2012;17(3):
157–62.
2therapy 1 8 ( 2 0 1 3 ) 133–138 137
8. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning
analysis (RPA) of prognostic factors in three radiation therapy
oncology group (RTOG) brain metastases trials. Int J Radiat
Oncol Biol Phys 1997;37:745–51.
9. Sperduto PW, Berkey B, Gaspar LE, et al. A new prognostic
index and comparison to three other indices for patients
with brain metastases: an analysis of 1,960 patients in the
RTOG database. Int J Radiat Oncol Biol Phys 2008;70:510–4.
0. Patchell RA, Tibbs PA, Regine WF,  et al. Postoperative
radiotherapy in the treatment of single metastases to the
brain: a randomized trial. JAMA 1998;280:1485–9.
1. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery
plus whole-brain radiation therapy vs stereotactic
radiosurgery alone for treatment of brain metastases: a
randomized controlled trial. JAMA 2006;295:2483–91.
2. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients
with brain metastases treated with radiosurgery or
radiosurgery plus whole-brain irradiation: a randomised
controlled trial. Lancet Oncol 2009;10:1037–44.
3. Kocher M, Sofﬁetti R, Abacioglu U, et al. Adjuvant whole-
brain radiotherapy versus observation after radiosurgery or
surgical resection of one to three cerebral metastases: results
of  the EORTC 22952-26001 study. J Clin Oncol 2011;29(2):134–41.
4. Abe E, Aoyama H. The role of whole brain radiation therapy
for  the management of brain metastases in the era of
stereotactic radiosurgery. Curr Oncol Rep 2012 Feb;14(1):79–84.
5. Aoyama H. Radiation therapy for brain metastases in breast
cancer patients. Breast Cancer 2011;18(4):244–51.
6. Fernandes G, Pocinho R, Travancinha C, Netto E, Roldao M.
Quality of life and radiotherapy in brain metastasis patients.
Rep  Pract Oncol Radiother. Article available online at http://
www.sciencedirect.com/science/article/pii/S150713671200129
(05.09.12), http://dx.doi.org/10.1016/j.rpor.2012.08.003
7. Aoyama H, Tago M, Kato N, et al. Neurocognitive function of
patients with brain metastasis who received either whole
brain radiotherapy plus stereotactic radiosurgery or
radiosurgery alone. Int J Radiat Oncol Biol Phys 2007;68:1388–95.
8. Scoccianti S, Ricardi U. Treatment of brain metastases: review
of  phase III randomized controlled trials. Radiother Oncol
2012;102:168–79.
9. Gondi V, Tomé Wa, Mehta MP. Why avoid the hippocampus?
A  comprehensive review. Radiother Oncol 2010;97(December
(3)):370–6.
0. Li J, Bentzen SM, Renschler M, et al. Regression after
whole-brain radiation therapy for brain metastases
correlates with survival and improved neurocognitive
function. J Clin Oncol 2007;25:1260–6.
1. Delattre JY, Krol G, Thaler HT, et al. Distribution of brain
metastases. Arch Neurol 1988;45:741–4.
2. Barret A, Dobbs J, Morris S, Roques T. Cerebral metastases. In:
Barret A, Dobbs J, Morris S, Roques T, editors. Practical
radiotherapy planning. London: Hodder Arnold; 2009. p. 227–30.
3. Abayomi OK. Pathogenesis of irradiation-induced cognitive
dysfunction. Acta Oncol 1996;35:659–63.
4. Monje ML, Mizumatsu S, Fike JR, et al. Irradiation induces
neural precursor-cell dysfunction. Nat Med 2002;8:
955–62.
5. Mizumatsu S, Monje ML, Morhardt DR, et al. Extreme
sensitivity of adult neurogenesis to low doses of
X-irradiation. Cancer Res 2003;63:4021–7.
6. Gondi V, Tome WA, Marsh J, et al. Estimated risk of
perihippocampal disease progression after hippocampal
avoidance during whole-brain radiotherapy: safety proﬁle for
RTOG 0933. Radiother Oncol 2010;95(3):327–31.
7. Palacova M, Svoboda M, Fabian P, et al. Tumor phenotype and
characteristics of metastatic brain involment in breast cancer
patients: potential clinical consequences, ASCO annual
meeting proceedings 2009. J Clin Oncol 2009;27(15):1026.
d rad
2
2
3
3
3
3
3
3
3
3
3138  reports of practical oncology an
8. Scoccianti S, Detti B, Cipressi S, et al. Changes in
neurocognitive functioning and quality of life in adult
patients with brain tumors treated with radiotherapy. J
Neurooncol 2012;108:291–308.
9. Monje ML, Palmer T. Radiation injury and neurogenesis. Curr
Opin Neurol 2003;16:129–34.
0. Eriksson PS, Perﬁlieva E, Bjork-Eriksson T, et al. Neurogenesis
in  the adult human hippocampus. Nat Med 1998;4:1313–7.
1. Gould E, Beylin A, Tanapat P, et al. Learning enhances adult
neurogenesis in the hippocampal formation. Nat Neurosci
1999;2:260–5.
2. Marsh JC, Gielda BT, Herskovic AM, Abrams RA. Cognitive
sparing during the administration of whole brain
radiotherapy and prophylactic cranial irradiation: current
concepts and approaches. J Oncol 2010:198–208.
3. van Kesteren Z, Belderbos J, van Herk M, et al. A practical
technique to avoid the hippocampus in prophylactic cranial
irradiation for lung cancer. Radiother Oncol 2012;102(February
(2)):225–7.
4. Mehta MP. A phase II trial of hippocampal avoidance during
whole brain radiotherapy for brain metastases. RTOG 0933iotherapy 1 8 ( 2 0 1 3 ) 133–138
study protocol. Available online at http://www.rtog.org/
ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0933
(last accessed 09.09.12).
5. Bayer SA. Changes in the total number of dentate granule
cells in juvenile and adult rats: a correlated volumetric and
3H-thymidine autoradiographic study. Exp Brain Res
1982;46:315–23.
6. Collier TJ, Quirk GJ, Routtenberg A. Separable roles of
hippocampal granule cells in forgetting and pyramidal cells
in  remembering spatial information. Brain Res
1987;409:316–28.
7. Jalali R, Mallick I, Dutta D, et al. Factors inﬂuencing
neurocognitive outcomes in young patients with benign and
low-grade brain tumors treated with stereotactic conformal
radiotherapy. Int J Radiat Oncol Biol Phys 2010;77:
974–9.
8. Gondi V, Tolakanahalli R, Mehta MP, et al.
Hippocampal-sparing whole-brain radiotherapy: a “how-to”
technique using helical tomotherapy and linear
accelerator-based intensity-modulated radiotherapy. Int J
Radiat Oncol Biol Phys 2010;78:1244–52.
